Standard pain management regimen — Competitive Intelligence Brief

Standard pain management regimen (Standard pain management regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: opioid. Area: Pain management.

phase 3 opioid opioid receptors Pain management Small molecule

Target snapshot

Standard pain management regimen (Standard pain management regimen) — Cedars-Sinai Medical Center. This drug works by targeting the opioid receptors in the brain to reduce pain perception.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard pain management regimen TARGET	Standard pain management regimen	Cedars-Sinai Medical Center	phase 3	opioid	opioid receptors
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Desflurane with remifentanil	Desflurane with remifentanil	Chung-Ang University Hosptial, Chung-Ang University College of Medicine	marketed	Volatile anesthetic with opioid analgesic	GABA receptors (desflurane); mu-opioid receptors (remifentanil)
Codeine paracetamol	Codeine paracetamol	Napp Pharmaceuticals Limited	marketed	Opioid analgesic combination	Opioid receptors (μ, δ, κ); cyclooxygenase (COX-1, COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (opioid class)

1. Norwegian University of Science and Technology · 2 drugs in this class
2. Cari Health Inc. · 1 drug in this class
3. Cedars-Sinai Medical Center · 1 drug in this class
4. Depomed · 1 drug in this class
5. Mundipharma Pharmaceuticals B.V. · 1 drug in this class
6. St. Olavs Hospital · 1 drug in this class
7. Talphera, Inc · 1 drug in this class
8. The Hospital for Sick Children · 1 drug in this class
9. University of Monastir · 1 drug in this class
10. University of Sao Paulo · 1 drug in this class